Abstract Number: 1558 • ACR Convergence 2021
Therapy Based Outcomes in Patients with Multisystem Inflammatory Syndrome in Children: A Single Center Study
Background/Purpose: Management and outcomes of multisystem inflammatory syndrome in children (MIS-C) remain under investigation and vary by institution. This study aimed to describe the outcomes…Abstract Number: 1559 • ACR Convergence 2021
Potential Predictors of Requirement for Mechanical Ventilation in Cases of COVID-19 Related Multisystem Inflammatory Syndrome in Children (MIS-C): Results of a Hospital-based Cohort Study from South India
Background/Purpose: COVID-19 related multisystem inflammatory syndrome in children (MIS-C) has varied clinical presentation ranging from fever with mild gastrointestinal and/or mucocutaneous changes to life threatening…Abstract Number: 1560 • ACR Convergence 2021
A Multidisciplinary Timely Approach to Initiate Immunosuppressive Biologic Therapy and Improve COVID-19 Cytokine Storm Syndrome Outcome
Background/Purpose: Coronavirus disease (COVID-19) patients can progress to a state of unregulated inflammation called cytokine storm syndrome (CSS). A multi-disciplinary approach is needed to identify…Abstract Number: 1561 • ACR Convergence 2021
Prevalence of SARS-CoV2 Infection in Diseases Inflammatory Rheumatology in the Rheumatology Service of the Hospital Docente Padre Billini, Dominican Republic
Background/Purpose: SARS-CoV-2 infection is caused by a new coronavirus. The World Health Organization (WHO) had information about the existence of this new virus on December…Abstract Number: 1562 • ACR Convergence 2021
B Cell Reconstitution Is Strongly Associated with COVID-19 Vaccine Responsiveness in Rheumatic Disease Patients Treated with Rituximab
Background/Purpose: Rituximab (RTX) has previously been shown to impair antibody response to vaccines such as influenza and streptococcus. Recently, diminished COVID-19 vaccine responsiveness in RTX…Abstract Number: 1563 • ACR Convergence 2021
Clinical Characteristics and Management of Olecranon and Prepatellar Septic Bursitis in a Multicenter Study
Background/Purpose: Septic bursitis (SB) is a common medical problem. However, there are no current guidelines for managing the condition. The study aims to describe the…Abstract Number: 1564 • ACR Convergence 2021
Nailfold Capillaroscopy Characterization in COVID-19: A Case Control Study
Background/Purpose: Nailfold capillaroscopy is a relatively easy-to-access, low-cost clinical tool that could help identify early coagulopathy in subjects with SARS-CoV-2, but specific findings vs. controls…Abstract Number: 1565 • ACR Convergence 2021
Causal Mediation Analysis of the Relationship of Canakinumab’s Protective Effect Against Gout Flares and High-sensitivity C-reactive Protein in the CANTOS Trial
Background/Purpose: Previous analyses in the CANTOS trial demonstrated a benefit of canakinumab (CAN; IL-1β inhibitor) on gout flares. We aimed to quantify the mediating role…Abstract Number: 1566 • ACR Convergence 2021
Hyperuricemia Is Associated with Vascular Endothelial Dysfunction – the Impact of Hyperuricemia on Flow Mediated and Nitroglycerin Mediated Dilatation of the Brachial Artery
Background/Purpose: Vascular endothelial cells line the entire circulatory system, these cells have very distinct and unique functions that are paramount to vascular biology. Hyperuricemia has…Abstract Number: 1567 • ACR Convergence 2021
Pharmacokinetics and Pharmacodynamics of Anthocyanins After Oral Administration of Oral Tart Cherry Juice Concentrate to Gout Patients
Background/Purpose: Tart cherries (TC) contain high levels of anthocyanins that exert potent antioxidant and anti-inflammatory effects. Approximately 50% of gout patients report using TC to…Abstract Number: 1568 • ACR Convergence 2021
AR882, a Potent and Selective Uricosuric Agent, Showed Effectiveness in Patients with Various Degrees of Renal Impairment
Background/Purpose: AR882 is a novel, potent and selective uric acid transporter 1 (URAT1) inhibitor in Phase 2 development for the treatment of hyperuricemia and gout.…Abstract Number: 1569 • ACR Convergence 2021
Effect of Elevated Serum Urate on Kidney Function: Analysis of a Randomized Controlled Trial of Inosine Supplementation
Background/Purpose: Observational studies have reported that serum urate associates with development and progression of kidney disease. However, it is uncertain whether elevated serum urate directly…Abstract Number: 1570 • ACR Convergence 2021
AR882, a Novel Uricosuric Agent, Exhibited Favorable Pharmacokinetic Profile and Balanced Excretion and Metabolic Pathways in a Human AME Study
Background/Purpose: AR882, a novel uric acid transporter 1 (URAT1) inhibitor is being developed for the treatment of gout with hyperuricemia. In Phase 1 and Phase…Abstract Number: 1571 • ACR Convergence 2021
Elevated Lactate, Procalcitonin Levels and SIRS (Systemic Inflammatory Response Syndrome) in a Subset of Patients with Gout
Background/Purpose: The intense inflammatory cascade of acute gouty inflammation makes it difficult to differentiate clinically between acute gouty inflammation and sepsis, particularly since they can…Abstract Number: 1572 • ACR Convergence 2021
Ultrasound Signs of Gout in a Population with Asymptomatic Hyperuricemia
Background/Purpose: Hyperuricemia is a common biological abnormality, often clinically asymptomatic. However, it can announce a gout and be linked to many diseases such as metabolic…
- « Previous Page
- 1
- …
- 807
- 808
- 809
- 810
- 811
- …
- 2607
- Next Page »
